Amoxycillin 250 mg Dispersible Tab
Amoxycillin is a broad-spectrum aminopenicillin antibiotic that exerts bactericidal activity by irreversibly binding to penicillin-binding proteins (PBPs) on the bacterial inner membrane. This inhibits the transpeptidase step of peptidoglycan cross-linking — the final stage of bacterial cell wall synthesis. The resulting cell wall defect causes osmotic imbalance, structural failure, and bacterial lysis.
At 250mg per dispersible tablet, this formulation is specifically calibrated for paediatric and lower-weight adult patients where a full 500mg dose would exceed the weight-based therapeutic target. The dispersible format is critical: the tablet disintegrates completely in water or can be chewed, producing a consistent suspension without the stability concerns of pre-reconstituted liquids. This makes it particularly practical for communities where refrigeration is unreliable.
Amoxycillin 250mg DT covers Streptococcus pyogenes, S. pneumoniae (susceptible strains), Haemophilus influenzae (non-beta-lactamase-producing), E. coli, Proteus mirabilis, and Enterococcus faecalis — the organisms most commonly responsible for paediatric ENT, respiratory, dental, and urinary tract infections managed in the outpatient setting.
STRIKEMOX™ 250 DT is indicated for mild to moderate bacterial infections in paediatric patients and lower-weight adults where the 250mg dose provides appropriate weight-based drug exposure.
Paediatric ENT Infections: Acute pharyngitis caused by Group A beta-haemolytic Streptococcus — a primary indication where a complete 10-day amoxycillin course remains the standard of care for prevention of rheumatic fever. Also effective for acute otitis media (in combination with watchful waiting criteria) and acute sinusitis caused by susceptible S. pneumoniae.
Dental Infections: Acute dentoalveolar abscess and periapical infections in younger patients and adults with lower body weight. Used prophylactically in dental procedures in patients at risk of bacterial endocarditis.
Respiratory Tract Infections: Community-acquired pneumonia caused by susceptible S. pneumoniae and H. influenzae in children managed in the outpatient setting. Acute exacerbations of chronic bronchitis in paediatric patients with underlying lung disease.
Urinary Tract Infections: Uncomplicated cystitis in children caused by susceptible E. coli and Proteus mirabilis. Weight-based dosing at 25–45mg/kg/day ensures adequate urinary drug concentrations for eradication.
Skin Infections: Mild impetigo and superficial cellulitis caused by susceptible Streptococcus pyogenes in children.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
The paediatric antibiotic market in India is dominated by suspensions and dry syrups — but these have a critical limitation: they require refrigeration after reconstitution and must be discarded after 7 days. In rural and semi-urban markets where cold chain access is limited, reconstituted syrups frequently degrade before the course is complete.
STRIKEMOX™ 250 DT solves this by delivering amoxycillin in a thermostable dispersible tablet format that doesn't require refrigeration at any point. For prescribers in remote or peri-urban settings, this makes a meaningful difference in treatment compliance and clinical outcomes.
For franchise partners, dispersible tablets represent a premium segment within the paediatric antibiotic category. The unique format commands a higher MRP than equivalent-dose dry syrups while offering a genuine clinical advantage — a combination that builds prescriber loyalty and patient satisfaction. Manufactured to WHO-GMP standards by Seclis Labs' partner facilities.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.